Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, acquired by Novo Nordisk, a Danish healthcare company and world leader in diabetes care, in 1986 and has been part of the pharmaceutical group since then.
On 1 September 2015 the company’s name was changed to Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of products such as Recombinant Insulin for cell growth media and pharmaceutical grade Benzalkonium Chloride for the pharmaceutical and personal care industries.
Novo Nordisk Pharmatech A/S is a leading global supplier of high-quality ingredients for the biopharmaceutical and pharmaceutical industries. The company has attracted an extensive roster of leading pharmaceutical companies through unsurpassed product quality, manufacturing and quality control, regulatory documentation, precision delivery and a comprehensive risk mitigation strategy.
Our history started in 1949:
1949 – The Ferrosan Fine Chemicals factory is established, part of the Ferrosan Group
1986 – Novo Industries acquire the Ferrosan Group
1989 – Merger of Novo Industries and Nordisk Gentofte to become Novo Nordisk A/S
1990 – Novo Nordisk initiates the sale of the Ferrosan Group but keeps the site in Koege. Ferrosan Fine Chemicals becomes a limited company and a fully owned subsidiary of Novo Nordisk A/S
1991 – First GMP approval by the Danish Medicines Agency for the manufacture of Quats products
1992 – The company name is changed to FeF Chemicals A/S and was ISO 9002 certified
1995 – Novo Nordisk sells the remaining of the Ferrosan Group
2001/2005 – Certificate of Suitability (CEP) for Benzalkonium Chloride and Cetrimide products
2002 – ISO 9001:2000 & ISO 14001:1996 certified
2004 – Fully integrated in the Product Supply/Devices & Sourcing business unit of Novo Nordisk
2005 – ISO 14001:2004 certified
2009 – OHSAS 18001 certified
2010 – Fully integrated in the Product Supply business unit of Novo Nordisk A/S, Denmark – a 12 billion US$ diabetes Care and Biopharmaceuticals company
2011 – Acquiring sales and distribution of Insulin Human for cell growth media
2012 – Full acquisition of Insulin Human business and building of classified room facility
2015 – FeF Chemicals A/S changes name to Novo Nordisk Pharmatech A/S
2016 – FDA inspected
2018 – ISO 9001:2015 certified
2018 – ISO 14001:2015 certified
2019 – Establishment of Singapore Branch Office
2020 – ISO 45001 certified
2021 – Establishment of Branch Office in Boston, USA
2022 – Strategic partnership with Novozymes
2022 – Affinity Resins to Novo Nordisk
2023 – Enterokinase and 2G ALP to Novo Nordisk
Click here to read more about us.
